Live price temporarily unavailable.
DENTSPLY SIRONA (XRAY) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $3.75B | $3.99B | $3.99B | $4.02B | $3.34B | $4.23B | $3.92B | $3.96B | $3.79B | $3.68B |
| Growth (year over year) | +40.0% | +6.6% | −0.2% | +0.9% | −17.0% | +26.7% | −7.3% | +1.1% | −4.3% | −3.0% |
| Gross profit | $2.00B | $2.19B | $2.07B | $2.16B | $1.66B | $2.35B | $2.13B | $2.09B | $1.96B | $1.84B |
| Gross margin | 53.4% | 54.8% | 51.9% | 53.8% | 49.6% | 55.5% | 54.2% | 52.6% | 51.6% | 50.0% |
| Operating income | $454.7M | −$1.56B | −$958.0M | $353.0M | −$3.00M | $608.0M | −$937.0M | −$85.0M | −$879.0M | −$422.0M |
| Operating margin | 12.1% | −39.1% | −24.0% | 8.8% | −0.1% | 14.4% | −23.9% | −2.1% | −23.2% | −11.5% |
| Net income | $429.9M | −$1.55B | −$1.01B | $256.0M | −$73.0M | $411.0M | −$950.0M | −$132.0M | −$910.0M | −$598.0M |
| Net margin | 11.5% | −38.8% | −25.4% | 6.4% | −2.2% | 9.7% | −24.2% | −3.3% | −24.0% | −16.3% |
| EPS (diluted) | $1.94 | −$6.76 | −$4.51 | $1.14 | −$0.33 | $1.87 | −$4.41 | −$0.62 | −$4.48 | −$3.00 |
| Balance sheet | ||||||||||
| Cash and equivalents | $383.9M | $320.6M | $309.6M | $405.0M | $438.0M | $339.0M | $365.0M | $334.0M | $272.0M | $326.0M |
| Total assets | $11.6B | $10.4B | $8.69B | $8.60B | $9.35B | $9.24B | $7.64B | $7.37B | $5.75B | $5.43B |
| Total liabilities | $3.43B | $3.75B | $3.55B | $3.51B | $4.42B | $4.24B | $3.83B | $4.08B | $3.81B | $4.09B |
| Long-term debt | $1.51B | $1.61B | $1.56B | $1.43B | $1.98B | $1.91B | $1.83B | $1.80B | $1.59B | $2.02B |
| Shareholders' equity | $8.11B | $6.62B | $5.12B | $5.09B | $4.93B | $5.00B | $3.81B | $3.29B | $1.94B | $1.34B |
| Cash flow | ||||||||||
| Operating cash flow | $563.4M | $601.9M | $500.0M | $639.0M | $649.0M | $657.0M | $517.0M | $377.0M | $461.0M | $235.0M |
| Capital expenditure | $125.0M | $144.3M | $183.0M | $123.0M | $87.0M | $142.0M | $149.0M | $149.0M | $180.0M | $131.0M |
| Free cash flow | $438.4M | $457.6M | $317.0M | $516.0M | $562.0M | $515.0M | $368.0M | $228.0M | $281.0M | $104.0M |
| Dividends paid | $64.6M | $78.3M | $79.0M | $81.0M | $88.0M | $92.0M | $104.0M | $116.0M | $126.0M | $128.0M |
| Share buybacks | $813.9M | $401.4M | $250.0M | $260.0M | $140.0M | $200.0M | $150.0M | $300.0M | $250.0M | $0 |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $951.0M | $905.0M | $879.0M | $936.0M | $904.0M | $961.0M | $880.0M | $898.0M |
| Growth (year over year) | +0.4% | −10.6% | −7.8% | −4.9% | −4.9% | +6.2% | +0.1% | −4.1% |
| Gross profit | $495.0M | $446.0M | $466.0M | $490.0M | $441.0M | $443.0M | $427.0M | $493.0M |
| Gross margin | 52.1% | 49.3% | 53.0% | 52.4% | 48.8% | 46.1% | 48.5% | 54.9% |
| Operating income | −$462.0M | −$509.0M | $63.0M | −$128.0M | −$218.0M | −$139.0M | −$35.0M | $82.0M |
| Operating margin | −48.6% | −56.2% | 7.2% | −13.7% | −24.1% | −14.5% | −4.0% | 9.1% |
| Net income | −$494.0M | −$430.0M | $20.0M | −$45.0M | −$427.0M | −$146.0M | −$10.0M | $37.0M |
| Net margin | −51.9% | −47.5% | 2.3% | −4.8% | −47.2% | −15.2% | −1.1% | 4.1% |
| EPS (diluted) | −$2.46 | −$2.09 | $0.10 | −$0.22 | −$2.14 | −$0.74 | −$0.05 | $0.18 |
| Balance sheet | ||||||||
| Cash and equivalents | $296.0M | $272.0M | $398.0M | $359.0M | $363.0M | $326.0M | $190.0M | $239.0M |
| Total assets | $6.63B | $5.75B | $6.05B | $6.07B | $5.65B | $5.43B | $5.23B | $5.20B |
| Total liabilities | $4.14B | $3.81B | $4.04B | $4.11B | $4.17B | $4.09B | $3.91B | $3.85B |
| Long-term debt | $1.79B | $1.59B | $1.59B | $2.22B | $2.02B | $2.02B | $2.01B | $2.00B |
| Shareholders' equity | $2.49B | $1.94B | $2.01B | $1.96B | $1.48B | $1.34B | $1.32B | $1.35B |
| Cash flow | ||||||||
| Operating cash flow | $141.0M | $87.0M | $7.00M | $48.0M | $79.0M | $101.0M | $40.0M | $99.0M |
| Capital expenditure | $43.0M | $51.0M | $19.0M | $32.0M | $39.0M | $41.0M | $52.0M | $44.0M |
| Free cash flow | $98.0M | $36.0M | −$12.0M | $16.0M | $40.0M | $60.0M | −$12.0M | $55.0M |
| Dividends paid | $33.0M | $31.0M | $32.0M | $32.0M | $32.0M | $32.0M | $32.0M | $0 |
| Share buybacks | $100.0M | $0 | — | — | $0 | $0 | — | — |
From DENTSPLY SIRONA's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning DENTSPLY SIRONA in our feed yet.